[A20-96] Ozanimod (multiple sclerosis) - Addendum to Commission A20-59
Last updated 07.01.2021
Project no.:
A20-96
Commission:
Commission awarded on 25.11.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Head and nerves
Indication:
| Adults with relapsing remitting multiple sclerosis (RRMS) |
Result of dossier assessment:
| Treatment-naive patients or patients whose RRMS is not highly active under disease-modifying therapy: unchanged (proof of considerable added benefit). Highly active RRMS despite therapy for which switch within the basic therapy is an option: now proof of major added benefit for men; for women: proof of considerable added benefit. |
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A20-59 | Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
07.01.2021 A G-BA decision was published.